KURZWEIL RAY

Director Ray Kurzweil sells 4,910 UTHR shares ($2.4M) at $489.02; stock near 52-week highs, post-transaction holdings 12.7K shares

Ray Kurzweil, as Director, sold 4,910 shares of United Therapeutics at $489.02 on 2026-03-04, reducing his holdings by 27.9% to 12,670 shares and generating $2,401,088.20 in proceeds. The sale occurs with the stock trading -9.4% from its 52-week high of $535.10, in a company reporting strong fundamentals (P/E 15.06, Net income $338.7M, annual revenue growth +10.6%). Notably, Kurzweil's prior five sales at this ticker posted uniformly positive 90-day returns (ranging +0.7% to +2.0%), indicating he has not established a pattern of selling ahead of declines—all prior same-ticker exits were followed by gains. His cross-ticker track record shows a 44.44% well-timed sell rate with average 90-day returns of +0.5%, suggesting mixed timing discipline across names.

Director Ray Kurzweil sells 15,000 shares of UTHR for $4.8M across 9 transactions; post-sale holding drops to 12,080 shares (-55.4%)

Ray Kurzweil, a Director at United Therapeutics, executed 9 separate sales on 2025-02-28 totaling 15,000 shares (15.0K shares) for $4,755,151.45 ($4.8M), with a blended average price of $317.01. This sale reduces his holdings from 27,080 shares to 12,080 shares, representing a -55.4% reduction in his pre-transaction position. The stock has declined -11.7% over the past 30 days and is trading 24.4% below its 52-week high of $410.00 at the current price of $310.03. While the company maintains strong fundamentals—including a P/E of 10.54, annual revenue growth of +23.6%, and a recent quarterly net income of $309.1M—the significant reduction in director holdings warrants attention to whether this reflects broader strategic considerations or personal liquidity decisions.